Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 26.4
(-2.22%)
SEK 26.4
(-2.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 53.22 Million SEK | 31.53% |
| 2022 | 40.46 Million SEK | 24.59% |
| 2021 | 32.47 Million SEK | -16.07% |
| 2020 | 38.69 Million SEK | 447.28% |
| 2019 | 7.07 Million SEK | 4603.82% |
| 2018 | -157 Thousand SEK | 98.45% |
| 2017 | -10.14 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 65.87 Million SEK | 23.78% |
| 2024 Q3 | 116.32 Million SEK | 179.92% |
| 2024 Q2 | 71.79 Million SEK | 8.97% |
| 2023 Q3 | 53.02 Million SEK | 8.73% |
| 2023 Q4 | 53.22 Million SEK | 0.38% |
| 2023 Q1 | 53.33 Million SEK | 31.81% |
| 2023 Q2 | 48.76 Million SEK | -8.57% |
| 2023 FY | 53.22 Million SEK | 31.53% |
| 2022 Q3 | 46.68 Million SEK | 9.46% |
| 2022 Q2 | 42.64 Million SEK | 6.45% |
| 2022 Q1 | 40.06 Million SEK | 23.35% |
| 2022 FY | 40.46 Million SEK | 24.59% |
| 2022 Q4 | 40.46 Million SEK | -13.32% |
| 2021 Q1 | 17.86 Million SEK | -53.83% |
| 2021 FY | 32.47 Million SEK | -16.07% |
| 2021 Q4 | 32.47 Million SEK | -5.38% |
| 2021 Q3 | 34.32 Million SEK | 38.03% |
| 2021 Q2 | 24.86 Million SEK | 39.18% |
| 2020 FY | 38.69 Million SEK | 447.28% |
| 2020 Q3 | 21.11 Million SEK | -43.02% |
| 2020 Q2 | 37.05 Million SEK | 435.3% |
| 2020 Q1 | 6.92 Million SEK | -2.09% |
| 2020 Q4 | 38.69 Million SEK | 83.25% |
| 2019 Q4 | 7.07 Million SEK | 0.0% |
| 2019 FY | 7.07 Million SEK | 4603.82% |
| 2019 Q1 | 2.24 Million SEK | 0.0% |
| 2018 FY | -157 Thousand SEK | 98.45% |
| 2017 FY | -10.14 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 260.31% |
| Biovica International AB (publ) | -58.73 Million SEK | 190.612% |
| Cantargia AB (publ) | -139.74 Million SEK | 138.085% |
| CombiGene AB (publ) | -101.44 Million SEK | 152.467% |
| Cyxone AB (publ) | -16.67 Million SEK | 419.274% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 1890.814% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 281.136% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 195.235% |
| Fluicell AB (publ) | -2.76 Million SEK | 2026.276% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 116.174% |
| Mendus AB (publ) | -96.29 Million SEK | 155.271% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 138.526% |
| I-Tech AB | -83.26 Million SEK | 163.922% |
| Intervacc AB (publ) | -88.16 Million SEK | 160.371% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 266.702% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 379.239% |
| OncoZenge AB (publ) | -12.62 Million SEK | 521.502% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 206.587% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 67.953% |
| Lipum AB (publ) | -8.46 Million SEK | 728.742% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 206.401% |
| Ziccum AB (publ) | -2.13 Million SEK | 2590.547% |
| BioArctic AB (publ) | -606.58 Million SEK | 108.774% |
| Genovis AB (publ.) | -43.94 Million SEK | 221.124% |
| Camurus AB (publ) | -1.16 Billion SEK | 104.567% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 163.555% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 235.145% |
| Aptahem AB (publ) | 2.9 Million SEK | -1729.823% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 115.953% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 141.1% |
| Kancera AB (publ) | -45.69 Million SEK | 216.482% |
| Saniona AB (publ) | 40.44 Million SEK | -31.587% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 217.706% |
| AcouSort AB (publ) | -23.98 Million SEK | 321.892% |
| Xintela AB (publ) | -7.8 Million SEK | 781.56% |
| Abliva AB (publ) | -57.24 Million SEK | 192.982% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 164.747% |
| Amniotics AB (publ) | -5.63 Million SEK | 1045.011% |
| 2cureX AB (publ) | -13.4 Million SEK | 497.098% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 2562.888% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -885.611% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 60.49% |
| Biosergen AB | -1.88 Million SEK | 2926.5% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | -159.498% |
| Corline Biomedical AB | -17.01 Million SEK | 412.856% |
| NextCell Pharma AB | -46.79 Million SEK | 213.747% |
| Nanologica AB (publ) | -9.38 Million SEK | 666.926% |
| LIDDS AB (publ) | -13.51 Million SEK | 493.894% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 127.336% |
| BioInvent International AB (publ) | -236.3 Million SEK | 122.523% |
| SynAct Pharma AB | -61.75 Million SEK | 186.18% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 348.531% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 502.315% |
| Alzinova AB (publ) | -21.22 Million SEK | 350.744% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 355.966% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 179.532% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 1127.289% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 163.557% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 5866.306% |
| Simris Alg AB (publ) | 85.07 Million SEK | 37.44% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 164.838% |